Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study

Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study

Abstract Background No randomized clinical trials have directly compared the cardiorenal effectiveness of empagliflozin and GLP-1RA agents with demonstrated cardioprotective effects in patients with a broad spectrum of cardiovascular risk. We reported the final-year results of the EMPRISE study, a m...

Full description

Bibliographic Details
Main Authors: Phyo T. Htoo, Helen Tesfaye, Sebastian Schneeweiss, Deborah J. Wexler, Brendan M. Everett, Robert J. Glynn, Niklas Schmedt, Lisette Koeneman, Anouk Déruaz-Luyet, Julie M. Paik, Elisabetta Patorno
Format: Article
Language:English
Published: BMC 2024-02-01
Series:Cardiovascular Diabetology
Subjects:
Empagliflozin
SGLT2i
GLP-1RA
Cardiovascular disease
Type 2 diabetes
Chronic kidney disease
Online Access:https://doi.org/10.1186/s12933-024-02150-0

Similar Items

Similar Items